Cipher’s leadership has decades of experience and a proven record of success in all facets needed to efficiently develop and commercialize dermatology products.
Dedication to our vision is paramount to our success as we expand our product offerings and presence in North America.
Interim Chief Executive Officer
Vice President, Scientific & Medical Affairs
Dr. Diane Gajewczyk, has more than 25 years of pharmaceutical industry experience in the research, clinical development and commercialization of pharmaceutical, biologics, vaccine and medical device products.
Prior to joining Cipher, Dr. Gajewczyk held the position of Senior Director, Medical Affairs with Galderma Canada, where she was responsible for medical and regulatory strategy and was involved in the registration and launch of a number of products. Previously, Dr. Gajewczyk spent almost ten years at Biovail Corporation in several senior positions, including Senior Director, Medical & Scientific Affairs, leading the scientific aspects of corporate development transactions. Prior to focusing on medical and scientific affairs, she spent 12 years in pharmaceutical R&D at Sanofi Pasteur where she developed numerous patents and conducted IND-enabling studies for novel therapeutics.
Dr. Gajewczyk obtained her PhD in Microbiology and Immunology from the University of Toronto, as well as her MBA from the Richard Ivey School of Business at Western University.